Agota Apati | Stem Cell Based Disease Modelling | Best Researcher Award

Posted on by Cognitive Scientist Awards

Dr. Agota Apati | Stem Cell Based Disease Modelling | Best Researcher Award

Dr. Ágota Apáti, PhD, DSc, is a distinguished Hungarian molecular biologist and Senior Research Associate at the Institute of Molecular Life Sciences, Research Centre for Natural Sciences. She leads the Pluripotent Stem Cell Laboratory and is renowned for establishing Hungary’s first human pluripotent stem cell lab. With over 70 publications and an H-index of 25, her work is widely recognized internationally. Dr. Apáti’s research encompasses human iPSC-derived disease models, membrane transporters, and cellular signaling pathways, with implications in schizophrenia, diabetes, and rare syndromes. She has supervised numerous PhD students and maintains active roles in both national and international scientific societies. Her commitment to translational stem cell research and ethical scientific practice positions her as a leading figure in the field of regenerative medicine and cellular therapeutics.

Profile

🎓 Education

Dr. Ágota Apáti holds a Master of Science (MSc) degree in Chemistry from Eötvös Loránd University of Sciences, Budapest (1984–1989). She later pursued doctoral studies and earned her PhD from Semmelweis Medical University (1998–2003), focusing on molecular and cellular aspects of hematology and immunology. Her academic training blends rigorous biochemical education with advanced medical sciences, establishing a solid foundation for her research career in stem cell biology and cellular therapeutics. Through continuous engagement in teaching and supervising graduate students, she has also remained an integral part of academic development at Hungary’s premier institutions. Her strong interdisciplinary background supports her work on complex cellular processes and disease modeling, and she is also a Doctor of Science (DSc, 2024) from the Hungarian Academy of Sciences—an honor awarded for substantial contributions to biomedical research in Hungary.

🧪 Experience

With over three decades of research experience, Dr. Ágota Apáti began her scientific career as a Research Fellow at Semmelweis Medical University (1989–1993). She progressed through multiple institutions, including the National Institute of Haematology and Immunology (1993–2004) and the National Blood Service (2005–2013), where she led various molecular biology projects. Between 2013 and 2023, she was a Senior Research Associate and lab head at the Institute of Enzymology, Hungarian Academy of Sciences. Since 2023, she continues her leadership as Laboratory Head at the Institute of Molecular Life Sciences under HUNREN. She has consistently taught and mentored postgraduate students in biochemistry, hematology, immunology, and membrane biology. Dr. Apáti’s collaborative and interdisciplinary projects have helped develop multiple disease models and cellular assays. Her scientific leadership has been instrumental in expanding Hungary’s role in cutting-edge stem cell research and molecular diagnostics.

🏅 Awards and Honors

Dr. Ágota Apáti has been recognized both nationally and internationally for her contributions to biomedical research. Early in her career, she received the prestigious UNIDO award during the ICRO course on RNA structure and function in Trieste, Italy (1994). In 2024, she was awarded the Doctor of Science (DSc) degree by the Hungarian Academy of Sciences—a distinguished title granted to researchers with a substantial, impactful body of scientific work. Her membership in renowned scientific organizations, such as the International Society for Stem Cell Research (ISSCR), Hungarian Society of Biology, Hungarian Society of Biochemistry, and the Hungarian Medical Research Council’s Ethical Board for Human Reproduction, underscores her stature in the field. These accolades not only reflect her scientific excellence but also her contributions to ethical research practice, public health, and mentoring within the scientific community, cementing her reputation as a key contributor to molecular life sciences.

🔬 Research Focus

Dr. Apáti’s research centers on pluripotent stem cells, disease modeling, and cellular signaling. She specializes in generating and differentiating human induced pluripotent stem cells (iPSCs) into neuronal, cardiac, mesenchymal, and endothelial lineages. Her work extends into disease modeling for schizophrenia, arteriosclerosis, diabetes, DiGeorge syndrome, and Frank-Ter Haar syndrome using patient-derived iPSC lines and CRISPR-based genome editing. She has developed cellular reporter systems to study membrane transporter function and calcium signaling pathways, significantly advancing understanding in neuropsychiatric and cardiovascular disorders. Through integrative omics and 3D organoid models, Dr. Apáti’s lab explores metabolic and genetic dysregulation in human pathologies. Her translational research aims to identify drug targets and therapeutic strategies using patient-specific cell lines. She also investigates multidrug resistance in stem cells and cancer, contributing to better clinical interventions. Her multidisciplinary projects bridge fundamental biology with clinical relevance, making her a vital contributor to regenerative medicine and personalized therapy.

✅ Conclusion

Dr. Ágota Apáti is a trailblazing scientist whose pioneering work in human stem cell research, disease modeling, and membrane biology continues to shape translational medicine, with a sustained commitment to research excellence, scientific mentorship, and ethical innovation in biomedical sciences.

Publications

  • Haloperidol, Olanzapine, and Risperidone Induce Morphological Changes in an In Vitro Model of Human Hippocampal Neurogenesis

    Biomolecules
    2024-06 | Journal article | Author
    DOI: 10.3390/biom14060688
    CONTRIBUTORS: Bálint Jezsó; Sára Kálmán; Kiara Gitta Farkas; Edit Hathy; Katalin Vincze; Dzsenifer Kovács-Schoblocher; Julianna Lilienberg; Csongor Tordai; Zsofia Nemoda; László Homolya et al.

  • Partial Disturbance of Microprocessor Function in Human Stem Cells Carrying a Heterozygous Mutation in the DGCR8 Gene

    Genes
    2022-10 | Journal article | Author
    DOI: 10.3390/genes13111925
    CONTRIBUTORS: Dóra Reé; Ábel Fóthi; Nóra Varga; Orsolya Kolacsek; Tamas Orban; Agota Apat

  • A Novel Cell-Based Model for a Rare Disease: The Tks4-KO Human Embryonic Stem Cell Line as a Frank-Ter Haar Syndrome Model System

    International Journal of Molecular Sciences
    2022-08 | Journal article | Author
    DOI: 10.3390/ijms23158803
    CONTRIBUTORS: Loretta László; Hédi Maczelka; Tamás Takács; Anita Kurilla; Álmos Tilajka; László Buday; Vas Virag; Agota Apati
  • Synthesis and Systematic Investigation of Lepidiline A and Its Gold(I), Silver(I), and Copper(I) Complexes Using In Vitro Cancer Models and Multipotent Stem Cells

 

Marta Comes Carsí | Psychiatry and ophthalmology | Women Researcher Award

Posted on by Cognitive Scientist Awards

Mrs. Marta Comes Carsí | Psychiatry and ophthalmology | Women Researcher Award

Hospital Clínico Universitario de Valencia, Spain

Mrs. Marta Comes Carsí is a Spanish ophthalmologist from Valencia with extensive clinical and academic expertise in visual sciences, retina, and ocular pathologies. Born on November 12, 1992, she currently serves as a Facultativo Especialista in Ophthalmology at the Hospital Clínico Universitario de Valencia. Her medical career is marked by specialized training across top hospitals in Spain, including Barcelona and Valencia, and advanced postgraduate studies in retina, uveitis, and clinical ophthalmology. With multiple master’s degrees and international certifications from the European Board of Ophthalmology and the International Council of Ophthalmology, Mrs. Comes Carsí combines a strong academic foundation with practical excellence. Her research explores structural and functional alterations of the retina, especially in psychiatric conditions, and has been published in prestigious ophthalmological journals. Fluent in English and Catalan, she actively contributes to continuing medical education and integrates evidence-based practices in clinical care.

Profile

🎓 Education

Mrs. Marta Comes Carsí obtained her medical degree from the Universitat de València in 2016, laying a strong foundation for her specialization in ophthalmology. She then completed a Master’s in Clinical Medicine at Universidad Camilo José Cela (2017), followed by multiple postgraduate degrees at Universidad Tecnológica de las Islas Canarias in Retina and Uveitis, Clinical Ophthalmology, and Ocular Pathologies (2024). She earned the European Board of Ophthalmology Diploma (EBO) and multiple certifications from the International Council of Ophthalmology (ICO) in Clinical Ophthalmology, Visual Sciences, and Optics. Her extensive additional training includes accredited university courses in surgical techniques, pediatric glaucoma, corneal diseases, and ocular inflammation. This multidisciplinary academic background equips her with the knowledge to manage complex ocular conditions and to contribute significantly to academic research and clinical teaching. Her education reflects a continuous commitment to staying updated with evolving practices and innovations in visual science and eye health.

🧪 Experience

Mrs. Marta Comes Carsí has accumulated a wide range of clinical experience through her progressive roles in leading Spanish medical institutions. She began her residency at Hospital Clínico y Provincial de Barcelona in 2017 and continued at the Hospital Clínico Universitario de Valencia from 2020 to 2024. Her dedication and expertise earned her a permanent position as a Facultativo Especialista in Ophthalmology at the same Valencia hospital, where she now works part-time. Mrs. Comes Carsí’s clinical work spans general ophthalmology, retinal pathologies, anterior segment imaging, and pediatric ocular disorders. Her experience also includes performing ophthalmologic surgeries and diagnosing complex visual system disorders. She actively participates in scientific and academic programs, blending patient care with educational involvement. Her clinical background, enriched with hands-on training and high-level certifications, reflects a comprehensive and evolving practice in visual health, making her a reliable clinician, researcher, and educator in the field of ophthalmology.

🏅 Awards and Honors

Mrs. Marta Comes Carsí’s commitment to academic and clinical excellence has been recognized through several prestigious achievements. She was awarded the European Board of Ophthalmology (EBO) Diploma in 2024, a significant credential demonstrating her advanced expertise across European standards. Additionally, she earned certifications from the International Council of Ophthalmology in Clinical Ophthalmology, Visual Sciences, and Optics—honors that underscore her global standing in ophthalmic education. Her dedication to continuing education is evident in her completion of specialized university-accredited courses in glaucoma, surgical ophthalmology, corneal diseases, and pediatric pathologies. These honors signify her commitment to lifelong learning and delivering the highest standards of care in ophthalmology. Her active involvement in continuing education programs and international evaluations confirms her drive for excellence and positions her as a highly respected ophthalmologist committed to best practices, academic advancement, and patient-centered care.

🔬 Research Focus

Mrs. Marta Comes Carsí’s research primarily focuses on the intersection of ophthalmology and systemic or neuropsychiatric conditions, particularly studying structural and functional retinal changes. Her recent work includes investigations into visual function and retinal morphology in patients with bipolar disorder, indicating a multidisciplinary approach that integrates psychiatry and ophthalmology. She also contributes to anterior segment imaging studies, such as iris abnormalities using optical coherence tomography (OCT). Her publications, appearing in Archivos de la Sociedad Española de Oftalmología, highlight her emphasis on evidence-based clinical advancements. Mrs. Comes Carsí applies her research findings to refine diagnostic accuracy and therapeutic approaches in complex ocular pathologies. Her focus on retinal diagnostics and systemic ocular manifestations supports the advancement of personalized ophthalmic care. By combining advanced imaging, clinical insight, and inter-disciplinary research, she is contributing to a broader understanding of ocular biomarkers relevant to both ophthalmology and systemic disease diagnosis.

✅ Conclusion

Mrs. Marta Comes Carsí exemplifies the integration of clinical expertise, academic rigor, and research innovation in modern ophthalmology. With a solid educational foundation, diverse hospital experience, and internationally recognized certifications, she advances patient care while contributing to scientific understanding of ocular diseases. Her work stands at the forefront of visual science and clinical excellence.

Publications

  • Marta Comes Carsí; Delia Hernández Pérez; Antonio Miguel Duch Samper. Subretinal hemorrhages
    with subfoveal involvement after blunt ocular trauma, in a patient with pseudoxanthoma elasticum and
    angioid streaks. Archivos de la Sociedad Española de Oftalmología (English Edition). 99 – 9, pp. 412.
    Elsevier BV, 22/06/2024. DOI: 10.1016/j.oftale.2024.05.013. Epub 2024 Jun 22.>. ISSN 2173-5794

  • Marta Comes Carsí; Noemí Ruiz Del Río; Antonio Miguel Duch Samper. Myopic macular pit with
    scleral dehiscence in highly myopic patient. Archivos de la Sociedad Española de Oftalmología
    (English Edition). Elsevier BV, 20/07/2024. DOI: 10.1016/j.oftale.2024.07.008>. ISSN 2173-5794
  • Marta Comes Carsí; Elena Gracia Rovira; Laura Manfreda Domínguez; Vicente Tomás Pérez
    Torregrosa; John Paul Liscombe Sepúlveda; Antonio Miguel Duch Samper. Oclusión combinada de
    vena central de la retina y arteria ciliorretiniana en dos pacientes jóvenes. Archivos de la Sociedad
    Espanola de Oftalmologia. Elsevier BV, 19/08/2024. https://doi.org/10.1016/j.oftal.2024.08.006.>.
    ISSN 0365-6691
  • Noemí Ruiz Del Río; Marta Comes Carsí; Leyre Sanz Gallen. Roséola sifilítica iridiana. Utilidad de la
    tomografía de coherencia óptica de segmento anterior. Archivos de la Sociedad Espanola de
    Oftalmologia. Elsevier BV, 24/08/2024. https://doi.org/10.1016/j.oftal.2024.08.004>. ISSN 0365-6691
  • Marta Comes Carsi; José Miguel Vilaplana Mora; Laura Manfreda Domínguez; Carlos Cañete
    Nicolás; Antonio Miguel Duch Samper. Alteraciones en la función visual y en la estructura retiniana
    de los pacientes con trastorno bipolar. Archivos de la sociedad española de oftalmología. (España):
    elsevier, 05/2025. <https://doi.org/10.1016/j.oftal.2025.03.007>.
  • Marta Comes Carsí; Sergio Alfredo Maugard Tepper; Antonio Miguel Duch Samper. Mamilaciones
    de iris bilaterales. Imagen de tomografía de coherencia óptica del segmento anterior.ARCHIVOS DE
    LA sociedad española de oftalmología. 04/2025.<https://doi.org/10.1016/j.oftal.2024.11.005>.
  • Marta Comes Carsí; Sergio Alfredo MAUGARD TEPPER; Amparo Lanuza García; Antonio Miguel
    Duch Samper. Orbital abscess surgery in a patient with odontogenic pansinusitis. Acta
    ophthalmologica. 100 – S275, pp. 1755 -3768. John Wiley & Sons, 20/12/2022.
    https://doi.org/10.1111/j.1755-3768.2022.0267>. ISSN 1755-375X

 

Alaa Abd-Elsayed | Neuromidulation | Best Researcher Award

Posted on by Cognitive Scientist Awards

Dr. Alaa Abd-Elsayed | Neuromidulation | Best Researcher Award

Dr. Alaa Abd-Elsayed 🇺🇸 is an American board-certified anesthesiologist and pain medicine specialist at the University of Wisconsin-Madison 🏥, recognized for his leadership, groundbreaking research 🔬, and compassionate patient care 💉, with a prolific academic career as a professor, director, and global speaker 🎤, blending clinical excellence, innovation, and education 📚 in pain management, with over two decades of medical service and leadership roles across Egypt 🇪🇬 and the U.S. 🇺🇸, while holding numerous prestigious certifications 🏅, published research, and leadership awards 🏆, he stands as a dedicated pioneer in improving chronic pain therapy 🔥 and anesthesiology practice worldwide 🌍.

Profile

Education 🎓

Dr. Alaa’s academic journey began at Assuit University 🇪🇬, earning his MBBCh 🩺 in 2000 & MPH 🎓 in 2006; postgrad, he trained extensively in the U.S. 🇺🇸, completing internships, anesthesiology residency, and a pain medicine fellowship 🏥 at the University of Cincinnati 🎯, and a Clinical Research Fellowship at Cleveland Clinic 🧪; board-certified in anesthesiology & chronic pain medicine 💊, and a Certified Physician Executive (CPE) 🏆, he capped his academic prowess with an Executive MBA 🎓 in 2023, mastering both medicine & healthcare leadership 🧠, and attending diverse leadership programs 💼 from AAPL, UW Health, and Faulkner University, cementing a strong foundation in clinical care and strategic innovation ⚡.

Experience 👨‍🏫

With over 20 years in medicine 🩺, Dr. Alaa has held roles from intern 👨‍⚕️ in Egypt 🇪🇬 to Associate Professor 📖, First Division Chief, and Medical Director at UW-Madison 🇺🇸; he’s led UW Health Pain Services 🔥, pioneering chronic pain medicine management 💊; his journey spanned positions at Assuit University, Cleveland Clinic, and University of Cincinnati 🏥; he’s served as chief fellow, staff anesthesiologist, researcher 🔬, educator 📚, and leader, combining advanced clinical practice 🏆 with administrative excellence 💼, mentoring future physicians while driving cutting-edge research 🚀 and pain medicine innovations 🌟.

Awards & Recognitions 🏅

Dr. Alaa’s distinguished career is crowned with awards 🌟 like the Raj/Racz Excellence Award 🥇, Physician of the Year 🏅, America’s Top Doctors 👏, Fellow of ASA 🧠, and recognition as a World Expert 🌍 in pain by Expertscape; multiple top research, poster 🖼️, and abstract prizes 🧾 from ASIPP, MARC, ASPN, ASA, INS & WSA 🏆 highlight his prolific contributions, while his books 📚 were ranked among the best in anesthesiology and pain medicine 💊; his research has shaped clinical practices 🌡️ and his leadership has been applauded across national and global stages 🎤, underlining his impact as a clinician, educator, and thought leader 💡.

Research Interests 🔬

Dr. Alaa’s research explores pain management innovation 🔥, neuromodulation ⚡, spinal cord stimulation 🧠, dorsal root ganglion therapies 💉, and anesthesiology outcomes 🧾; he’s passionate about translating bench-to-bedside discoveries 🏥, optimizing patient-centered chronic pain therapies 💊, and advancing perioperative safety 🌡️; his peer-reviewed publications 📚, clinical trials 🧪, and systematic reviews ⚗️ have influenced global practices 🌍, securing his place among top 0.05% scholars worldwide 🏆; his scientific vision combines clinical evidence, bioethics, and real-world health solutions for pain relief and anesthetic care 🧠💡.

Publications 

Pin Wang | Neuroimmunology | Best Researcher Award

Posted on by Cognitive Scientist Awards

Dr. Pin Wang | Neuroimmunology | Best Researcher Award

Dr. Pin Wang, a female medical doctor and postdoctoral researcher, is an Associate Chief Physician in Neurology at the Second Hospital of Shandong University. She earned her PhD in Neurology from Shandong University in 2009 and was a visiting scholar at the NIH, USA. She specializes in neuroimmunology, focusing on multiple sclerosis and related disorders. Dr. Wang has led research funded by the Shandong Natural Science Foundation and the Department of Education, with multiple SCI-indexed publications.

Profile

Education 🎓

Dr. Wang obtained her PhD in Neurology from Shandong University School of Medicine in 2009. From 2012 to 2013, she trained at the National Institute of Neurological Disorders and Stroke (NINDS), NIH, under Dr. Bibiana Bielekova, focusing on immune-mediated neurological diseases. Her education integrates clinical neurology, research, and teaching, positioning her as an expert in demyelinating diseases and neuroimmune disorders.

Experience 👨‍🏫

Dr. Wang has extensive experience in neurology, combining clinical practice, teaching, and research. She worked at NIH, studying neuroimmune disease mechanisms and participated in the FDA-approved daclizumab clinical trials for multiple sclerosis. She is an Associate Chief Physician at Shandong University’s Second Hospital and actively contributes to patient care, student training, and neurological research, particularly in neuroimmunology.

Research Interests 🔬

Dr. Wang specializes in multiple sclerosis, neuromyelitis optica, myelitis, optic neuritis, acute disseminated encephalomyelitis, and myasthenia gravis. Her research explores immune-mediated neurological diseases, oxidative stress in demyelination, and environmental neurotoxins in neurodegenerative disorders like Alzheimer’s disease.

Dr. Wang has received funding from the Shandong Natural Science Foundation and the Department of Education for her research in neurological disorders. Her contributions to neuroimmunology have been recognized through multiple SCI publications and conference presentations. She plays an active role in professional neurology and immunology committees in Shandong Province.

Publications 📚

Jeevitha Gowda R | Cognitive impairment | Best Researcher Award

Posted on by Cognitive Scientist Awards

Ms. Jeevitha Gowda R | Cognitive impairment | Best Researcher Award

Assistant Professor, Alliance University, United Kingdom

🧠 Dr. Jeevitha Gowda R is a dedicated research scholar specializing in cognitive neuroscience and public health, with a strong focus on dementia prevention. She has expertise in developing cognitive screening tools, conducting neuropsychological assessments, and designing neuroscience-based interventions to enhance brain health. Currently serving as a Guest Faculty and Research Associate, she is passionate about bridging research with real-world applications. With proficiency in EEG, ERP, and data analysis, her work emphasizes cognitive aging, behavioral psychology, and mental well-being. Her research contributions include multiple conference presentations, publications, and cognitive training programs. She has received prestigious recognitions, including Best Paper Awards and research fellowships. Her commitment extends to community mental health programs, where she collaborates with NGOs and research institutions. Through her work, she aims to advance cognitive neuroscience and improve public health outcomes. 📚🔬

Profile

Education 🎓

🎓 Dr. Jeevitha Gowda R holds a Ph.D. in Cognitive Neuroscience and Public Health from Ramaiah University of Applied Sciences, Bengaluru (Thesis Submitted), focusing on developing cognitive tools for early dementia detection in primary healthcare settings. She earned a Master’s in Cognitive Neuroscience from JSS Academy of Higher Education, Mysuru (2018), ranking among the top 3 students, with coursework in neural cognition, psychological assessment, and clinical interventions. Her dissertation explored mental fatigue due to sleep deprivation using EEG and ERP. She completed her Bachelor’s in Life Sciences from JSS College for Women, Mysuru (2016), excelling in biochemistry, microbiology, and environmental psychology. Additionally, she trained at the Defence Institute of Psychological Studies (DRDO) and Narayana Health, Bengaluru, gaining hands-on experience in EEG, neuropsychological assessments, and cognitive therapy. Her interdisciplinary education combines neuroscience, psychology, and public health, preparing her for impactful research and innovation in brain health. 🧠📖

Experience 👨‍🏫

💼 Dr. Jeevitha Gowda R has extensive experience as a Research Associate at the Centre for Integrative Health and Well-Being (2020–Present), where she develops neuropsychological intervention tools and conducts cognitive behavioral therapy (CBT) programs. She also serves as a Senior Research Associate at Brighter Minds, focusing on cognitive enhancement and neuroscience-based training programs. As a Guest Lecturer at Ramaiah University of Applied Sciences (2021–Present), she teaches biostatistics, neurophysiology, and psychology. Her past clinical internships at DRDO and Narayana Health provided her with hands-on expertise in EEG, ERP, and neuropsychological assessments. She has conducted research on cognitive impairment, dementia screening, and sleep deprivation’s effects on cognition. Additionally, she has authored 50+ neuroscience articles, presented at international conferences, and collaborated with NGOs for mental health awareness. Her diverse experience integrates academic, clinical, and research-based expertise to advance cognitive neuroscience and public health. 🏥📊

Research Interests 🔬

🔬 Dr. Jeevitha Gowda R’s research bridges cognitive neuroscience, psychology, and public health, focusing on early dementia detection, cognitive aging, and neuropsychological interventions. She specializes in developing culturally relevant cognitive screening tools for primary healthcare, improving accessibility to dementia diagnostics. Her work explores neuropsychological assessments, EEG-based cognitive analysis, and behavioral interventions for enhancing mental well-being. She has conducted studies on sleep deprivation, cognitive impairment, and neurofeedback therapy. She collaborates with institutions like DRDO, Narayana Health, and Brighter Minds to implement neuroscience-driven programs. Her research extends to the psychological well-being of dementia caregivers, neurocognitive training for brain health, and integrating technology into mental health solutions. Through interdisciplinary studies and global research collaborations, she aims to advance early dementia detection methods and improve cognitive health strategies. Her work contributes to policy-making, clinical psychology, and public health initiatives. 🏥📊

Awards & Recognitions 🏅

🏆 Dr. Jeevitha Gowda R has received multiple accolades for her contributions to cognitive neuroscience and public health research. She won the Best Paper Award at the Epidemiology Foundation of India Conference (2023, Goa) for her groundbreaking work on dementia screening. Her research paper on cognitive tool validation earned a Special Mention at the International Dementia Conference (DEMCON-2024, IISC Bangalore). During her master’s, she ranked among the top 3 dissertations at JSS Academy of Higher Education. She was awarded the Senior Research Fellowship (SRF) by Ramaiah University of Applied Sciences (2022–2024) for her Ph.D. research. She has also secured research grants for projects on dementia detection and cognitive enhancement. Recognized for her impactful contributions, she collaborates with prestigious institutions, including DRDO and Narayana Health, to advance neuropsychological research. Her work continues to shape innovations in mental health and aging. 🎖️🧠

Publications 📚

  • Jeevitha Gowda R, Anish Mehta, Krishnamurthy Jayanna. (2025).
    Dementia: A Public Health Challenge in India. South Eastern European
    Journal of Public Health, 29–43. Retrieved from
    hps://www.seejph.com/index.php/seejph/article/view/3295 (Scopus)

  • Jeevitha Gowda R. The Impact of Cultural Beliefs and Stigma on
    Dementia Care and Diagnosis: A Scoping Review, 25 November 2024,
    PREPRINT (Version 1) available at Research Square
    hps://doi.org/10.21203/rs.3.rs-5519592/v1
  • Jeevitha Ramesh, Parimala Guruprasad (2024) Factors Affecting the
    Psychological Well-Being of Caregivers of Dementia Patients: A
    Thematic Review. Journal of Neurology Research Reviews & Reports.
    SRC/JNRRR-260
  • Development and Validation of Cognitive Screening Tools for
    Dementia Detection in Primary Care Seings: An Exploratory Pilot
    Study – Under review at International Journal of Geriatric Psychiatry.
    (Corresponding Author)
  • Burden of Cognitive Impairment Including Dementia, and Associated
    Risk Factors Among the Rural Population of South Karnataka, India –
    Under review at Journal of Public Health Research. (Corresponding
    Author)
  • Impact of Training Module on Lifestyle and Healthy Behaviours: An
    Exploratory Pilot in India – Under review at Journal Explore.
    (Co-Author)

Gerardo Fernandez | Eye tracking | Excellence in Innovation

Posted on by Cognitive Scientist Awards

Dr. Gerardo Fernandez | Eye tracking | Excellence in Innovation

Gerardo Abel Fernández 🇦🇷, born on October 29, 1976, in Bahía Blanca, Argentina, is a researcher specializing in neuroscience and cognitive science 🧠. He is a professor and adjunct researcher at CONICET, focusing on eye movement-based biomarkers for neurodegenerative diseases 👀. His work integrates philosophy, cognitive psychology, and technology to advance Alzheimer’s diagnosis 🏥.

Profile

Education 🎓

🎓 Gerardo Abel Fernández obtained a degree in Philosophy (2003) from Universidad Nacional del Sur (UNS), Argentina, with a specialization in Logic and Epistemology. He later pursued a PhD in Philosophy (2011) at UNS, with his thesis titled “Dynamic word processing during reading: Mental strategies driving visual exploration”, earning a perfect 10/10 with special mention. His academic journey includes postdoctoral research as a fellow at AGENCIA (ANPCYT) and the DAAD Max Planck Institute in Berlin. His educational background bridges philosophy, neuroscience, and cognitive psychology, forming a solid foundation for his pioneering research in eye movement analysis and Alzheimer’s biomarkers. His expertise in cognitive science and technological innovation has led to the development of diagnostic tools for early neurodegenerative disease detection. 📚🔍🧠

Experience 👨‍🏫

💼 Dr. Gerardo Abel Fernández has extensive experience in neuroscience research and technological innovation. He served as a Professor of Audiovisual Language at UNS (2011–2013) and is currently an Adjunct Researcher at CONICET, focusing on non-endemic degenerative pathologies. He has worked as a Visiting Scholar at Heriot-Watt University and Strathclyde University (UK), contributing to the development of eye-tracking biomarkers for Alzheimer’s disease. Dr. Fernández is also a scientific reviewer for prestigious journals like PlosOne, Journal of Alzheimer’s Disease, and Neuropsychologia. As CTO of Viewmind, he leads biocognitive and functional performance measurement innovations. He has patented cognitive evaluation methods and received grants from institutions like ANPCYT and DAAD. His interdisciplinary expertise spans cognitive neuroscience, machine learning applications in diagnostics, and technological development for neurodegenerative disease assessment. 🏅🔬👁️

Research Interests 🔬

🔬 Dr. Gerardo Abel Fernández specializes in cognitive neuroscience, neurodegenerative disease biomarkers, and eye-tracking technology. His research focuses on early Alzheimer’s detection through oculomotor behavior analysis. He has developed innovative methods to study visual exploration, reading difficulties, and memory impairments in neurodegenerative conditions. His work integrates machine learning and artificial intelligence for cognitive assessment tools. As a Visiting Scholar in the UK, he contributed to developing biomarkers for Alzheimer’s disease. His patented eye-tracking system has clinical applications in detecting mild cognitive impairment and Alzheimer’s disease. He has published extensively in peer-reviewed journals, exploring predictive eye movement models and their correlation with cognitive decline. His cutting-edge research bridges philosophy, neuroscience, and technology, offering non-invasive diagnostic solutions for early-stage neurodegeneration. His ultimate goal is to revolutionize cognitive healthcare through technological innovation. 🧠👁️📊

Awards & Recognitions 🏅

🏆 Dr. Gerardo Abel Fernández has received numerous awards for his contributions to neuroscience, cognitive evaluation, and Alzheimer’s diagnostics. His eye-tracking research for Alzheimer’s detection earned the Dr. José Borda Clinical Psychiatry Prize at the 22nd International Congress of Psychiatry. He won the Novartis Innovation Award for his work on measuring cognitive performance in health and disease. As CTO of Viewmind, his team received international recognition, including the Fit4Start Luxembourg Award for health applications and the Medica Innovation Prize in Düsseldorf. His research and patented cognitive evaluation equipment have been acknowledged by ANMAT (Argentina’s National Administration of Drugs, Foods, and Medical Technology) and INPI (Argentina’s National Patent Office). Dr. Fernández’s groundbreaking innovations in neurocognitive assessments have positioned him as a leading figure in technological advancements for early Alzheimer’s detection. 🏅🧠🔬

Publications 📚

  • Oculomotor behaviors and integrative memory functions in the alzheimer’s clinical syndrome

    Journal of Alzheimer’s Disease
    2021 | Journal article
    DOI: 10.3233/JAD-201189

  • A non-invasive tool for attention-deficit disorder analysis based on gaze tracks.

    ACM International Conference Proceeding Series
    2019 | Conference paper
    DOI: 10.1145/3309772.3309777

  • Microsaccadic behavior when developing a complex dynamical activity

    Journal of Integrative Neuroscience
    2018 | Journal article
    DOI: 10.3233/JIN-170057

    EID:

    2-s2.0-85053731401

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Posted on by Cognitive Scientist Awards

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication

Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

Posted on by Cognitive Scientist Awards

Dr. Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

 

 

Profile

Education

He completed his education at Org. Kenan Evren School from 2000 to 2008, followed by Gaziantep Anadolu High School from 2008 to 2012. He then pursued his medical training at Hacettepe University Faculty of Medicine from 2012 to 2018. After earning his medical degree, he continued his specialization in Plastic, Reconstructive, and Aesthetic Surgery as a resident at Hacettepe University Faculty of Medicine from November 2018 to February 2024. In April 2024, he joined Ankara Research and Training Hospital, where he continues to work in the Department of Plastic, Reconstructive, and Aesthetic Surgery.

 

Work experience

He has participated in various courses and workshops to enhance his expertise in plastic, reconstructive, and aesthetic surgery. He attended the Resident Ethics Course at Hacettepe University’s Department of History of Medicine and Medical Ethics on January 10-11, 2019. He also completed the 5th Basic Residency School organized by the Turkish Society of Plastic, Reconstructive, and Aesthetic Surgery in Bolu, Turkey, from January 22-25, 2020. Further advancing his skills, he took part in the 15th Advanced Residency School in Antalya, Turkey, from April 20-24, 2023. Additionally, he attended the 1st Cadaver Course of Craniofacial Anomaly and Maxillofacial Surgery at Hacettepe University on September 3-4, 2022, and the 1st Cadaver Course of Orthognathic Surgery at Koc University Hospital in Istanbul, Turkey, on September 7-8, 2022.

In addition to his clinical and surgical training, he has contributed to academic literature by co-authoring book chapters. He co-wrote Age-Related Changes in Trunk Aesthetics in Beauty, Aging, and Anti-Aging (1st ed., Elsevier, 2022) alongside G. G. Üstün and S. Yıldızdal. He also contributed to Dudak ve Damak Yarıkları Hacettepe Ekip Yaklaşım, co-authoring “Apert and Crouzon Syndrome” with İbrahim Vargel.

Awards

He has achieved remarkable academic success, securing 16th place in the National Examination for Specialty in Medicine among over 18,000 participants. Additionally, he ranked 571st in the National Student Selection and Placement Examination out of more than 2 million candidates.

He has actively participated in national meetings within his field, contributing to discussions and advancements in plastic, reconstructive, and aesthetic surgery. He attended the 41st National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Samsun, Turkey, from October 26-30, 2019. He also participated in the National Turkish Plastic Reconstructive and Aesthetic Surgery Eastern Mediterranean Meeting on Cleft Lip and Palate, held in Gaziantep, Turkey, from February 7-9, 2020. Furthermore, he attended the 43rd National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Antalya, Turkey, from November 10-14, 2021.

 

Publication

Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Posted on by Cognitive Scientist Awards

Prof Dr. Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Michal Schwartz (born 1 January 1950) is a professor of neuroimmunology at the Weizmann Institute of Science. She is active in the field of neurodegenerative diseases, particularly utilizing the immune system to help the brain fight terminal neurodegenerative brain diseases, such as Alzheimer’s disease and dementia.[3][1]

Schwartz’s studies have shown that the immune system supports a healthy brain’s function and is vital for healing and protecting the brain in case of injury or disease.[4]

Schwartz coined the term protective autoimmunity[5] and discovered roles for immune cells in repair and neurogenesis. She has been the elected chair of the International Society of Neuroimmunology (ISNI) since 2016.[6]

In 2023 Schwartz received the honorary Israel Prize for Life Sciences.

 

Profile

Education

Schwartz gained her Bachelor of Science in chemistry at the Hebrew University of Jerusalem in 1972. She received her Ph.D in Immunology in 1977 at the Weizmann Institute of Science, where she would later spend the majority of her career. She also spent time at the University of Michigan, Ann Arbor, researching nerve regeneration.[when?

 

Work experience

At the Weizmann Institute, she progressed from senior scientist in the Department of Neurobiology to full professor in 1998, and was then awarded the Maurice and Ilse Katz Professorial Chair in Neuroimmunology in 2016.[7] Schwartz’s work in neuroimmunology has encompassed a wide range of pathologies in the central nervous system (CNS), including injury, neurodegeneration, mental dysfunction, and aging. She coined the term protective autoimmunity and demonstrated the role of immune cells such as macrophages and T cells in spinal cord repair. She also identified specific brain areas for ‘cross talk’ between the CNS and the immune system. This cross-talk is important for recruiting immune cells and maintaining a healthy brain, and the disruption of this cross-talk can play a role in brain aging and neurodegenerative disease. She also showed this role in pregnancy and fetal brain development, where immune disruption in the mother can be linked to neurodevelopmental disorders in their children. Another focus of her work has been on repurposing cancer immunotherapies such as PD-1 blockers to treat neurodegenerative disorders, such as Alzheimer’s disease.

Macrophages

The Schwartz team discovered that bone marrow-derived macrophages are needed for central nervous system (CNS) repair. The brain-resident myeloid cells (the microglia), and infiltrating monocyte-derived macrophages are not redundant populations, despite their myeloid phenotype, and display distinct functions in resolution of brain inflammation.[8][9][10]

Autoimmunity

In her research, Schwartz discovered that the ability to cope with sterile CNS injuries requires support in the form of an adaptive immune response mediated by CD4+ T cells that recognize CNS antigens. She coined the concept of protective autoimmunity, to distinguish this response from autoimmune disease, in which the anti-self response escapes control. Over the years, it became clear that adaptive immunity is needed to facilitate the recruitment of immunoregulatory cells, including bone marrow-derived macrophages and FoxP3 regulatory T cells, though the balance between regulatory T cells and effector memory cells is different in the periphery versus the brain.[11][12][13]

Brain Homeostasis

Schwartz’s team discovered the role of adaptive systemic immune cells, and specifically T cells recognizing brain antigens (Protective autoimmune T cells), in supporting the cognitive capacity of the healthy brain, for lifelong neurogenesis, and functional brain plasticity. These observations paved the way for numerous additional discoveries in which the brain-immune axis was described.[14][15][16]

The Choroid Plexus

Schwartz’s team identified the brain’s choroid plexus (CP) within the blood-cerebrospinal fluid barrier as an immunological interface between the brain and the immune system. It serves as a niche that hosts immune cells, and as a physiological entry gate for leukocytes. Focusing on this unique niche within the brain led the Schwartz group to propose that IFN-γ holds the key to regulating CP gateway activity. Her team further showed that in brain aging and neurodegenerative diseases (studied using both mouse models and human samples), dysfunction of this interface is determined both by signals originating in the brain, and signals from the aged immune system, which led to the identification of Type-I Interferon (IFN-I) at the CP as a negative player, affecting the fate of the aging brain in general, and of microglia, in particular. A similar IFN-I signature at the CP was subsequently discovered by others in Alzheimer’s disease and in the postmortem brains of infected patients who died from COVID-19.[17][14][10]

Immunotherapy

The discovery that adaptive immunity plays a key role in brain function and repair, the need for bone marrow-derived macrophages to resolve local brain inflammation, the fact that Alzheimer’s disease (AD) and all forms of dementia are mainly age-related diseases, and the fact that the immune system is particularly affected by aging all led Schwartz to propose a new treatment for combating dementias. Schwartz suggested empowering systemic immunity, using a form of immunotherapy by modestly blocking the inhibitory immune checkpoint PD1/PD-L1 pathway.[citation needed] This treatment drives an immune-dependent cascade of events, that allows the harnessing of bone marrow-derived macrophages and regulatory T cells to help clear toxic factors from the diseased brain, and to arrest the local inflammation, thereby providing a comprehensive multi-factorial therapy through modification of multiple elements that go awry in AD. Schwartz’s patents for developing such immunotherapy for AD are licensed to a small Biopharma company, Immunobrain Checkpoint. The company is awaiting a clinical trial in AD patients, supported in part by the National Institute of Aging, the US National Institutes of Health, and The Alzheimer’s Association.[18][19][20][21][22][23]

Publication

1. Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame T, Peralta Ramos
J, Cahalon L, Krizhanovsky V, Schwartz M. 2024. Senescent microglia conserved in aging and
Alzheimer’s disease exhibit elevated TREM2 protein levels. Nat Neurosci 27: 1116-24
2. Tsitsou-Kampeli A, Suzzi S, Kenigsbuch M, Satomi A, Strobelt R, Singer O, Feldmesser E, Purnapatre
M, Colaiuta SP, David E, Cahalon L, Hahn O, Wyss-Coray T, Shaul Y, Amit I, Schwartz M. 2023.
Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis. Cell Rep
Med: 101278
3. Suzzi, S. Croese T., Ravid A., Gold O., Clark A., Medina A., Kitsberg D., Adam M., Vernon K., Kohnert
E., Shapira I., Malitsky S., Itkin M., Brandis A., Mehlman T., Salame T., Colaiuta S., Cahalon L.,Slyper
M., Greka A., Habib N., Schwartz M. 2023. N-acetylneuraminic acid links immune exhaustion and
accelerated memory deficit in diet-induced obese Alzheimer’s disease mouse model 2023. Nat. Commun.
14:1293.
4. Kenigsbuch M, Bost P, Halevi S, Chang Y, Chen S, Ma Q, Hajbi R, Schwikowski B, Bodenmiller B, Fu
H, Schwartz M*, Amit I* (equal contribution, and corresponding authors). 2022. A shared diseaseassociated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci 25: 876-86.
5. Dvir-Szternfeld R, Castellani G, Arad M, Cahalon L, Colaiuta SP, Keren-Shaul H, Croese T, Burgaletto
C, Baruch K, Ulland T, Colonna M, Weiner A, Amit I, Schwartz M. 2022. Alzheimer’s disease
modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in
mouse model of amyloidosis. Nature Aging 2: 60-73 (citations:17).
6. Ben-Yehuda H, Arad M, Peralta Ramos JM, Sharon E, Castellani G, Ferrera S, Cahalon L, Colaiuta SP,
Salame TM, Schwartz M. 2021. Key role of the CCR2-CCL2 axis in disease modification in a mouse
model of tauopathy. Mol Neurodegeneration 16: 39. (citations:20).
7. Cohen M, Giladi A, Raposo C, Zada M, Li B, Ruckh J, Deczkowska A, Mohar B, Shechter R, Lichtenstein
RG, Amit I, Schwartz M. 2021. Meningeal lymphoid structures are activated under acute and chronic
spinal cord pathologies. Life Sci Alliance 4: e202000907.
8. Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D,
Nguyen L, Marshall JL, Chen F, Zhang F, Kaplan T, Regev A, Schwartz M. 2020. Disease- associated
astrocytes in Alzheimer’s disease and aging. Nat Neurosci 23: 701-6. (citations:617).
9. Ben-Yehuda H, Matcovitch-Natan O, Kertser A, Spinrad A, Prinz M, Amit I, Schwartz M. 2020.
Maternal Type-I interferon signaling adversely affects the microglia and the behavior of the offspring
accompanied by increased sensitivity to stress. Mol Psychiatry 25: 1050-67 (Cover page).
10. Kertser A,Baruch K, Deczkowska A,Weiner A,Croese T, Kenigsbuch M,CooperI, Tsoory M,Ben- Hamo
S, Amit I, Schwartz M. 2019. Corticosteroid signaling at the brain-immune interface impedes coping with
severe psychological stress. Sci Adv 5: eaav4111. (citations:32).
11. Rosenzweig N, Dvir-Sternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P,
Cahalon L, Kertser A, Baruch K, Amit I, Weiner A, Schwartz M. 2019. PD-1/PD-L1 checkpoint blockade
harnesses monocyte-derived macrophages to combat cognitive impairment in a mouse model of tauassociated dementia. Nat Commun. 10: 465. (citations:141).
12. Deczkowska A, Matcovitch-Natan O, Tsitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A,
Singer O, David E, Winter RD, Smith KL, Kertser A, Baruch K, Rosenzweig N, Terem A, Prinz M,
Villeda S, Citri A, Amit I, Schwartz M. 2017. Mef2C restrains the microglial inflammatory response and
is lost in brain ageing in an IFN-I-dependent manner. Nat Commun 8: 717. (citations:212).
13. Cohen M, Ben-Yehuda H, Porat Z, Raposo C, Gordon S, Schwartz M. 2017. Newly formed endothelial
2
cells regulate myeloid cell activity following spinal cord injury via expression of CD200 ligand. J
Neurosci 37: 972-85.

Wei Jiang | Cognitive and neuropathology | Women Researcher Award

Posted on by Cognitive Scientist Awards

 Dr. Wei Jiang | Cognitive and neuropathology | Women Researcher Award

Medical University of South Carolina , United States

Her academic focus includes microbiome, B cell/autoantibody interactions, and disease pathogenesis, with particular emphasis on HIV, addictive drugs, and systemic lupus erythematosus (SLE). She is involved in several clinical and translational research projects, including R01DA059854 (Jiang & Sheng), investigating the impacts of drug abuse on autoantibodies and immune reconstitution in HIV. She also works on CSRD Merit I01 CX002422, exploring B cell-mediated immunological failure in HIV-infected individuals on antiretroviral therapy. Additionally, she contributes to NIDA-funded studies, such as R01DA055523, examining the oral microbiome’s effect on cognition in HIV-infected cannabis users, and R01DA059538, investigating HIV persistence in cocaine users. Furthermore, she collaborates on a Translational Science Award project exploring the oral microbiome’s impact on cognition in Alzheimer’s disease.

 

 

Profile

Education:

She earned her M.S. in Epidemiology and Biostatistics from Case Western Reserve University, Medical School, Cleveland, USA, in 2012. Prior to that, she completed a Postdoctoral fellowship at Case Western Reserve University, Medical School, Cleveland, USA, in 2008. She holds an M.S. in Immunology from Capital Medical University, Beijing, China, which she completed in 2001. She also received her M.D. in Internal Medicine from Capital Medical University, Beijing, China, in 1997.

BRIEF RESEARCH INTEREST STATEMENT:

She has 8 years of clinical experience in infectious diseases and 22 years of translational research experience in disease immunopathogenesis. As a corresponding author, she has published 52 peer-reviewed articles on microbiome and disease immunopathogenesis in high-profile journals like Microbiome, Arthritis & Rheumatology, J Autoimmunity, and EbioMedicine, bringing her total number of peer-reviewed publications to 101. As a physician-scientist, she has served as Principal Investigator on five R01 grants from NIAID or NIDA, along with a VA clinical merit grant, focusing on microbiomes, drug abuse, autoimmunity, and HIV immunopathogenesis. Her research primarily focuses on two major areas. The first is understanding the role of B cell perturbation and autoantibodies in disease pathogenesis, particularly in HIV and SLE. In 2017, her team first determined that autoimmunity impacts antiretroviral therapy outcomes in HIV without inducing autoimmune disease. This concept was later corroborated in studies on COVID-19. Her team is currently developing monoclonal autoantibodies and inhibitors to prevent anti-CD4 autoantibody binding, aiming to improve CD4+ T cell recovery and reduce morbidity in HIV patients. The second area of focus is the role of microbiomes in disease pathogenesis, including HIV, SLE, and drug abuse. She has identified the impact of disease-associated pathobionts on immune perturbations and disease progression, with findings validated in animal models. Her microbiome research is supported by R01DA055523.

TRAINING, PROFESSIONAL APPOINTMENTS

She currently serves on the Appointment, Promotion & Tenure (APT) committee in the Department of Microbiology and Immunology at the Medical University of South Carolina, a position she has held since 2024. She was promoted to Full Professor with tenure in the Department of Microbiology and Immunology, Division of Infectious Diseases, Department of Medicine at the same institution in 2023. She has been a Faculty Senator for the College of Medicine and a Research Health Scientist at the Ralph H. Johnson VA Medical Center since 2022. Additionally, she is a member of the Translational Science Laboratory IAC (2020-2022) and the MUSC College’s Curriculum Committee (2019-Present). She has held various positions at MUSC, including Associate Professor (2018-2022) and Assistant Professor (2012-2018) in the Department of Microbiology and Immunology. Since 2018, she has been a member of the Hollings Cancer Center at MUSC and has served on the award committee for the Advancement, Recruitment, and Retention of Women in Science. Her academic career began as an Instructor (2008-2012) and Research Associate (2002-2008) at Case Western Reserve University School of Medicine in Cleveland, OH.

AWARDS

She received her Chinese Board of Internal Medicine certification in Infectious Diseases in July 1997 and was certified as an Attending Medical Doctor in Infectious Diseases in November 1999 (No: 10203C089758). In July 1997, she also earned a Teacher Qualification from the Educational Institute, National Educational Committee in China (No: 971100071069382). Her licensure is from Beijing, China.

She has received several awards throughout her career, including the Laboratory Travel Grant from the American Association of Immunologists (AAI) in 2019, the MUSC High Impact Research Publication Award in 2019, and multiple travel grants from AAI for various international immunology congresses. She was awarded the Early Career Faculty Travel Grant by AAI and ECI in 2018 and 2017, and received the Travel Award and HIV Section Chair recognition at the 2016 International Congress of Immunology. In 2015, she was honored with the MUSC Foundation Developing Scholar Award and an Early Career Faculty Travel Grant from AAI. Her earlier achievements include multiple Young Investigator Awards from the 13th and 15th Conferences on Retroviruses and Opportunistic Infections (2006, 2008) and the Keystone Meeting on HIV Pathogenesis (2006, 2008). Additionally, she was recognized as an Outstanding Student Leader for five consecutive years during her medical school years from 1986 to 1991.

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS

She has held several key professional roles and memberships throughout her career. Since 2024, she has been serving as a mentor for the American Society for Microbiology (ASM) Future Leaders Mentorship Fellowship (FLMF) Program. She is a member of the Society on NeuroImmune Pharmacology 2024 committee and has been a Treasurer Elect for the Association of Chinese Virologists in America from 2022 to 2024. She has been a member of the American Society for Microbiology (ASM) since 2021 and the Infectious Diseases Society of America (IDSA) since 2020. She has also been serving on the Editorial Board of the Journal of Neuroimmune Pharmacology since 2019 and is a member of the Society on NeuroImmune Pharmacology. Additionally, she has been part of the Society of Chinese Bioscientists in America (SCBA) and the American College of Rheumatology since 2018. She has contributed as an award committee member for the Advancement, Recruitment, and Retention of Women in Science at the Medical University of South Carolina since 2017 and is an associate member of the Hollings Cancer Center at MUSC.

She is also an active member of the MUSC Oral Health Center, College of Dental Medicine, and the Medical University of South Carolina College of Graduate Studies. Her previous memberships include being part of the American Association of Immunologists from 2011 to 2021, the Center for AIDS Research from 2008 to 2012, and the AIDS Clinic Trial Group since 2008. Her certification in Chinese Board of Internal Medicine in Infectious Diseases dates back to 1997, along with her teacher qualification from the Educational Institute, National Educational Committee, China.

CURRENT RESEARCH PROJECTS

She is currently leading several impactful research projects. As the Principal Investigator (PI) on R01DA059854 (9/30/2024-5/31/2029), funded by NIDA with a total of $3,924,302, she is studying the impacts of drug abuse-mediated inflammatory perturbations on affinity maturation of anti-CD4 autoantibodies and poor immune reconstitution from ART in HIV. This project aims to understand the role of cocaine in autoimmunity and immune recovery in HIV patients. Her role in this project is as PI (25% effort).

She is also a multiPI on R01DA059538 (9/30/2023-7/31/2028), with a total of $1,724,585 from NIDA, investigating host gene isoforms contributing to HIV persistence in cocaine users. The study focuses on identifying gene isoforms associated with HIV infection in elite controllers and its implications for cocaine users. Her role is PI (25% effort).

In addition, she is the PI on I01CX002422 (3/1/2022-2/28/2026), funded by the VA Medical Center CSRD Merit with a total of $1,195,899. This project examines the mechanism of autoreactive B cell-mediated immunological failure in HIV-infected individuals on antiretroviral therapy despite virologic suppression. She is focused on understanding the molecular mechanisms of anti-CD4 IgG-producing B cells and the pathologic effects of anti-CD4 autoantibodies. Her role is PI with 62.5% effort.

Additionally, she is involved as multiPI on R01DA055523 (9/30/2022-7/31/2027), with a total funding of $1,731,992, where she is working alongside Fitting to investigate the effects of microbiome-related mechanisms on H

 Publication